This project was presented orally as a proffered paper at the United States and Canadian Academy of Pathology Annual Meeting in Baltimore, MD, March 2013.
CD34-positive superficial myxofibrosarcoma: a potential diagnostic pitfall†
Article first published online: 19 APR 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Journal of Cutaneous Pathology
Volume 40, Issue 7, pages 639–645, July 2013
How to Cite
CD34-positive superficial myxofibrosarcoma: a potential diagnostic pitfall., , , , , , .
- Issue published online: 16 JUN 2013
- Article first published online: 19 APR 2013
- Accepted manuscript online: 2 APR 2013 10:28AM EST
- Manuscript Accepted: 21 MAR 2013
- Manuscript Revised: 15 MAR 2013
- Manuscript Received: 11 JAN 2013
- soft tissue tumors
Myxofibrosarcoma (MFS) arises most commonly in the proximal extremities of the elderly, where it may involve subcutaneous and dermal tissues and masquerade as benign entities in limited biopsy samples. We encountered such a case, in which positivity for CD34 and morphologic features were initially wrongly interpreted as a ‘low-fat/fat-free’ spindle cell/pleomorphic lipoma. Case series have not assessed prevalence of CD34 reactivity among cutaneous examples of MFS.
We performed a systematic review of our institution's experience, selecting from among unequivocal MFS resection specimens those superficial cases in which a limited biopsy sample might prove difficult to interpret. These cases were immunostained for CD34 and tabulated for clinicopathologic characteristics.
After review of all MFS diagnoses over 5 years (n = 56), we identified a study group of superficial MFS for comparison to the index case (total n = 8). Of these, the index and three additional cases (4 of 8, 50%; 2 low, 2 high grade) demonstrated positive staining for CD34, with diffuse staining of spindled cells including cellular processes. Four additional cases showed no or equivocal/rare staining.
CD34 positivity should be recognized as prevalent among such cases and should not be inappropriately construed as inveighing against a diagnosis of MFS in favor of benign entities.